Skip to main content
Glama

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
      -  "company"
      -]New value: +[
      +  "company",
      +  "ticker"
      +]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/opensWorld/idempotent annotations, the description discloses substantial behavior: parallel fan-out, per-source fallback (GDELT→GNews), soft-failure of the USPTO patents source after April 2025, and the semantic that an empty fda_products section is expected for non-biologic companies. It even states that empty sections are real 'no data' rather than bugs, and that sources_used/sources_failed indicate what actually returned data.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and dense, but the length is justified by the tool's many output sections and fallback behaviors. It is front-loaded with the most important instruction ('ALWAYS PREFER over chaining single-pack lookups') and structured so an agent can quickly identify invocation rules, accepted inputs, and expected empty-section semantics. A slightly more organized layout would earn a 5.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Even with no output schema, the description enumerates every notable return field (cik, company_name, recent_filings, fundamentals, patents, federal_contracts, fda_products, hiring, news, LEI, sources_used/sources_failed) and explains what counts as expected non-data. It also covers all accepted input forms and resolution behavior, making it complete enough for an agent to invoke correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema already covers 100% of the parameter meanings, including accepted value shapes and the interchangeability of type values. The description reinforces this with examples and mentions name resolution, but does not add substantial semantic meaning beyond what the schema already provides.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete example queries and a definitive purpose: 'full cross-source profile of a US public company in ONE parallel call.' It also differentiates itself by explicitly recommending it over chaining single-pack SEC/XBRL/news lookups, and it enumerates exactly which data sources are fanned out across.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit guidance: 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view.' It also clarifies expected edge cases, such as private companies returning resolved:false with an explanatory notes line rather than a bare failure, which tells the agent when the tool is still appropriate.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.2/5.0
Disambiguation2/5

The tool set mixes OKX exchange tools with a large set of Pipeworx data query tools and prediction market tools. Many tools overlap in purpose, e.g., ask_pipeworx, deep_research, and ask_pipeworx_grounded all answer questions but with different modes. OKX tools like ticker and tickers are clear but the overall set is confusing.

Naming Consistency2/5

Naming is inconsistent: OKX tools use single nouns or underscores (ticker, order_book), Pipeworx tools use verb phrases (ask_pipeworx, validate_claim), and prediction market tools use prefixed names (polymarket_arbitrage, bet_research). No consistent pattern.

Tool Count2/5

43 tools is excessive for a coherent server. The scope is unclear—combining exchange, data lookup, and prediction market tools into one server results in a cluttered surface.

Completeness2/5

The server tries to cover too many domains. OKX coverage is decent, but the inclusion of many unrelated tools (e.g., generate_llms_txt, scan_dependency) makes the set feel incomplete for any single purpose. Gaps exist in each sub-domain due to the broad scope.